Research programme: HDV type 2 diabetes mellitus therapeutic - Diasome PharmaceuticalsAlternative Names: Oral HDV + novel T2DM candidate
Latest Information Update: 11 Dec 2015
At a glance
- Originator Diasome Pharmaceuticals
- Mechanism of Action Glucose modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 11 Dec 2015 Preclinical trials in Type-2 diabetes mellitus in USA (PO)